| Year |
Citation |
Score |
| 2023 |
Cui G, Botuyan MV, Drané P, Hu Q, Bragantini B, Thompson JR, Schuller DJ, Detappe A, Perfetti MT, James LI, Frye SV, Chowdhury D, Mer G. An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering. Nature Communications. 14: 6091. PMID 37773238 DOI: 10.1038/s41467-023-41821-6 |
0.753 |
|
| 2023 |
Cui G, Botuyan MV, Drané P, Hu Q, Bragantini B, Thompson JR, Schuller DJ, Perfetti MT, James LI, Frye SV, Chowdhury D, Mer G. An autoinhibited state of 53BP1 revealed by chemical probes and protein engineering. Biorxiv : the Preprint Server For Biology. PMID 37131705 DOI: 10.1101/2023.04.20.534960 |
0.753 |
|
| 2021 |
Suh JL, Bsteh D, Hart B, Si Y, Weaver TM, Pribitzer C, Lau R, Soni S, Ogana H, Rectenwald JM, Norris JL, Cholensky SH, Sagum C, Umana JD, Li D, ... ... Frye SV, et al. Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell Chemical Biology. PMID 34715055 DOI: 10.1016/j.chembiol.2021.10.003 |
0.317 |
|
| 2020 |
Puhl AC, Bogart JW, Haberman VA, Larson JE, Godoy AS, Norris-Drouin JL, Cholensky SH, Leisner TM, Frye SV, Parise LV, Bowers AA, Pearce KH. Discovery and Characterization of Peptide Inhibitors for CIB1. Acs Chemical Biology. PMID 32383857 DOI: 10.1021/Acschembio.0C00144 |
0.355 |
|
| 2020 |
Rectenwald JM, Guduru SKR, Dang Z, Collins LB, Liao YE, Norris-Drouin JL, Cholensky SH, Kaufmann KW, Hammond SM, Kireev DB, Frye SV, Pearce KH. Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins. Molecules (Basel, Switzerland). 25. PMID 32098353 DOI: 10.3390/Molecules25040979 |
0.391 |
|
| 2020 |
Barnes DE, Wang X, Frye SV, Earp HS, DeRyckere D, Barnes DK. Abstract 6388: MERTK and ROCK inhibitors mediate synergistic AML cell death and enhance therapeutic activity in combination with cytotoxic chemotherapy Cancer Research. 80: 6388-6388. DOI: 10.1158/1538-7445.Am2020-6388 |
0.353 |
|
| 2020 |
Yan D, Huelse J, Parker R, Tan Z, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib Cancer Research. 80: 1882-1882. DOI: 10.1158/1538-7445.Am2020-1882 |
0.341 |
|
| 2020 |
Maffuid KA, Torrice CD, Hardy B, Murphy WA, James LI, Kim WY, Frye SV, Pearce KJ, Crona DJ. Abstract 1743: Evaluation of the effects of combined chemical inhibition of PARP and BET proteins in preclinical models of urothelial bladder cancer Cancer Research. 80: 1743-1743. DOI: 10.1158/1538-7445.Am2020-1743 |
0.383 |
|
| 2019 |
Foley CA, Potjewyd F, Lamb KN, James LI, Frye SV. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay. Acs Chemical Biology. PMID 31846298 DOI: 10.1021/Acschembio.9B00972 |
0.36 |
|
| 2019 |
Da C, Zhang D, Stashko M, Vasileiadi E, Parker R, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, ... ... Frye SV, et al. Data-driven construction of anti-tumor agents with controlled polypharmacology. Journal of the American Chemical Society. PMID 31497954 DOI: 10.1021/Jacs.9B08660 |
0.373 |
|
| 2019 |
Holtzhausen A, Harris W, Ubil E, Hunter DM, Zhao J, Zhang Y, Zhang D, Liu Q, Wang X, Graham DK, Frye SV, Earp HS. TAM Family Receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunology Research. PMID 31451482 DOI: 10.1158/2326-6066.Cir-19-0008 |
0.333 |
|
| 2019 |
Lamb KN, Bsteh D, Dishman SN, Moussa HF, Fan H, Stuckey JI, Norris JL, Cholensky SH, Li D, Wang J, Sagum C, Stanton BZ, Bedford MT, Pearce KH, Kenakin TP, ... ... Frye SV, et al. Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7. Cell Chemical Biology. PMID 31422906 DOI: 10.1016/J.Chembiol.2019.07.013 |
0.394 |
|
| 2019 |
Wong JP, Stuhlmiller TJ, Giffin LC, Lin C, Bigi R, Zhao J, Zhang W, Bravo Cruz AG, Park SI, Earp HS, Dittmer DP, Frye SV, Wang X, Johnson GL, Damania B. Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31346082 DOI: 10.1073/Pnas.1903991116 |
0.327 |
|
| 2019 |
Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Science Signaling. 12. PMID 31311847 DOI: 10.1126/Scisignal.Aav7259 |
0.349 |
|
| 2019 |
Moussa HF, Bsteh D, Yelagandula R, Pribitzer C, Stecher K, Bartalska K, Michetti L, Wang J, Zepeda-Martinez JA, Elling U, Stuckey JI, James LI, Frye SV, Bell O. Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing. Nature Communications. 10: 1931. PMID 31036804 DOI: 10.1038/S41467-019-09628-6 |
0.325 |
|
| 2019 |
Suh JL, Barnash KD, Abramyan TM, Li F, The J, Engelberg IA, Vedadi M, Brown PJ, Kireev DB, Arrowsmith CH, James LI, Frye SV. Discovery of selective activators of PRC2 mutant EED-I363M. Scientific Reports. 9: 6524. PMID 31024026 DOI: 10.1038/S41598-019-43005-Z |
0.322 |
|
| 2019 |
Gu C, Stashko MA, Puhl-Rubio A, Chakraborty M, Chakraborty A, Frye SV, Pearce KH, Wang X, Shears SB, Wang H. Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure/Activity Analysis. Journal of Medicinal Chemistry. PMID 30624931 DOI: 10.2210/Pdb6M8D/Pdb |
0.36 |
|
| 2019 |
Yan D, Huelse J, Parker R, Wang X, Frye SV, Earp HS, DeRyckere D, Graham D. Abstract 4765: MERTK is a potential therapeutic target in osimertinib-resistant non-small cell lung cancer Cancer Research. 79: 4765-4765. DOI: 10.1158/1538-7445.Sabcs18-4765 |
0.355 |
|
| 2019 |
Summers RJ, Minson KA, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract A35: MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A35 |
0.315 |
|
| 2019 |
Minson KA, Vasileiadi E, Huey MG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 3037: Stromal cell activation of MAPK signaling pathways mediates resistance to MERTK inhibition in acute myeloid leukemia Cancer Research. 79: 3037-3037. DOI: 10.1158/1538-7445.Am2019-3037 |
0.327 |
|
| 2018 |
Hopcraft SE, Pattenden SG, James LI, Frye S, Dittmer DP, Damania B. Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. Plos Pathogens. 14: e1007267. PMID 30212584 DOI: 10.1371/Journal.Ppat.1007267 |
0.379 |
|
| 2018 |
Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. MERTK promotes resistance to irreversible EGFR tyrosine kinase inhibitors in non-small cell lung cancers expressing wild-type EGFR-family members. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30194074 DOI: 10.1158/1078-0432.Ccr-18-0040 |
0.314 |
|
| 2018 |
Suh JL, Watts B, Stuckey JI, Norris-Drouin JL, Cholensky SH, Dickson BM, An Y, Mathea S, Salah E, Knapp S, Khan A, Adams AT, Strahl BD, Sagum CA, Bedford MT, ... ... Frye SV, et al. Quantitative characterization of bivalent probes for a dual bromodomain protein, Transcription Initiation Factor TFIID subunit 1, TAF1. Biochemistry. PMID 29558110 DOI: 10.1021/Acs.Biochem.8B00150 |
0.335 |
|
| 2018 |
McDaniel NK, Cummings CT, Brand TM, Iida M, Hulse J, Pearson HE, Orbuch RA, Ondracek OJ, Davies KD, Gill P, Wang X, Frye SV, Earp HS, Kimple RJ, Harari PM, et al. Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A140 |
0.373 |
|
| 2017 |
Yan D, Wang X, Frye SV, Earp SH, DeRyckere D, Graham DK. Abstract 1082: MerTK promotes resistance to irreversible EGFR TKIs by activation of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR Cancer Research. 77: 1082-1082. DOI: 10.1158/1538-7445.Am2017-1082 |
0.348 |
|
| 2017 |
Barnash KD, Lamb KN, James LI, Frye SV. Peptide Technologies in the Development of Chemical Tools for Chromatin-Associated Machinery Drug Development Research. 78: 300-312. DOI: 10.1002/Ddr.21398 |
0.374 |
|
| 2016 |
Baughman BM, Wang H, An Y, Kireev D, Stashko MA, Jessen HJ, Pearce KH, Frye SV, Shears SB. A High-Throughput Screening-Compatible Strategy for the Identification of Inositol Pyrophosphate Kinase Inhibitors. Plos One. 11: e0164378. PMID 27736936 DOI: 10.1371/Journal.Pone.0164378 |
0.357 |
|
| 2016 |
Page LS, Wang X, Earp HS, Frye S, Jordan CT, Lee-Sherick AB. MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia Blood. 128: 4044-4044. DOI: 10.1182/Blood.V128.22.4044.4044 |
0.309 |
|
| 2016 |
Minson KA, Huey MG, Hill AA, Perez I, Wang X, Frye S, Earp HS, DeRyckere D, Graham DK. Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia Blood. 128: 2819-2819. DOI: 10.1182/Blood.V128.22.2819.2819 |
0.315 |
|
| 2015 |
Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, et al. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 6: 6722-36. PMID 25762638 DOI: 10.18632/Oncotarget.3156 |
0.352 |
|
| 2015 |
Da C, Stashko M, Jayakody C, Wang X, Janzen W, Frye S, Kireev D. Discovery of Mer kinase inhibitors by virtual screening using Structural Protein-Ligand Interaction Fingerprints. Bioorganic & Medicinal Chemistry. 23: 1096-101. PMID 25638502 DOI: 10.1016/J.Bmc.2015.01.001 |
0.376 |
|
| 2015 |
Perfetti MT, Baughman BM, Dickson BM, Mu Y, Cui G, Mader P, Dong A, Norris JL, Rothbart SB, Strahl BD, Brown PJ, Janzen WP, Arrowsmith CH, Mer G, McBride KM, ... ... Frye SV, et al. Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1. Acs Chemical Biology. 10: 1072-81. PMID 25590533 DOI: 10.1021/Cb500956G |
0.757 |
|
| 2015 |
Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 125: 346-57. PMID 25395428 DOI: 10.1182/Blood-2014-06-581082 |
0.434 |
|
| 2015 |
James LI, Stuckey JI, Baughman BM, Perfetti MT, Pattenden SG, Dickson BM, Norris JL, Cui G, Mader P, Dong A, Mu Y, Rothbart SB, Strahl BD, Min J, Brown PJ, ... ... Frye SV, et al. Abstract SY08-03: Targeting chromatin regulation for cancer therapy: progress towards chemical probes for methyl-lysine readers Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Sy08-03 |
0.752 |
|
| 2015 |
Graham D, DeRyckere D, Minson K, Smith C, Hill A, Huey M, Lasater E, Wang X, Shah N, Frye S, Shelton Earp H. Development of novel small molecule MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia Annals of Oncology. 26: ii6. DOI: 10.1093/Annonc/Mdv082.2 |
0.367 |
|
| 2014 |
Ma A, Yu W, Li F, Bleich RM, Herold JM, Butler KV, Norris JL, Korboukh V, Tripathy A, Janzen WP, Arrowsmith CH, Frye SV, Vedadi M, Brown PJ, Jin J. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. Journal of Medicinal Chemistry. 57: 6822-33. PMID 25032507 DOI: 10.1021/Jm500871S |
0.4 |
|
| 2014 |
DeRyckere D, Lee-Sherick AB, Hill AA, Page L, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia Blood. 124: 998-998. DOI: 10.1182/Blood.V124.21.998.998 |
0.356 |
|
| 2014 |
Minson KA, Smith CC, Lee-Sherick AB, DeRyckere D, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia Blood. 124: 3757-3757. DOI: 10.1182/Blood.V124.21.3757.3757 |
0.356 |
|
| 2014 |
Graham DK, DeRyckere D, Lee-Sherick A, Hill AA, Minson K, Xiaodong W, Zhang W, Liu J, Frye S, Earp HS. Abstract A37: MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A37 |
0.358 |
|
| 2014 |
Earp HS, Darr D, Zimmermann A, Clark K, Sharpless NE, Bergmeier W, Zhang W, Wang X, DeRyckere D, Frye S, Graham D. Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma Cancer Research. 74: 947-947. DOI: 10.1158/1538-7445.Am2014-947 |
0.376 |
|
| 2014 |
Teodorovic LS, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Eckhardt SG, Earp HS, Graham DK. Abstract 730: Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant melanoma cell lines Cancer Research. 74: 730-730. DOI: 10.1158/1538-7445.Am2014-730 |
0.34 |
|
| 2014 |
Fer ND, Harris E, Fox S, Zhou M, Simpson C, Liu J, Korboukh I, Hull-Ryde EA, Janzen WP, Frye SV, Monks A, Teicher B, Rapisarda A. Abstract 3741: Development and characterization of a cell based assay for the validation of mutant IDH1 inhibitors Cancer Research. 74: 3741-3741. DOI: 10.1158/1538-7445.Am2014-3741 |
0.367 |
|
| 2014 |
Jacobsen KM, DeRyckere D, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. Abstract 3637: Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer Cancer Research. 74: 3637-3637. DOI: 10.1158/1538-7445.Am2014-3637 |
0.304 |
|
| 2014 |
Sherick AL, Menachof K, Hill A, Rinella S, DeRyckere D, Liu J, Wang X, Frye S, Earp HS, Graham D. Abstract 1743: A dual FLT-3 and MER tyrosine kinase small molecule inhibitor in acute myeloid leukemia cell lines and patient samples Cancer Research. 74: 1743-1743. DOI: 10.1158/1538-7445.Am2014-1743 |
0.351 |
|
| 2014 |
Cummings CT, Davies KD, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Graham DK. Abstract 1742: Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer Cancer Research. 74: 1742-1742. DOI: 10.1158/1538-7445.Am2014-1742 |
0.377 |
|
| 2014 |
DeRyckere DA, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, Graham DK. Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia Cancer Research. 74: 1740-1740. DOI: 10.1158/1538-7445.Am2014-1740 |
0.399 |
|
| 2014 |
Newton TP, Cummings CT, Kirkpatrick GD, Hinz TK, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Heasley L, Graham DK. Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition Cancer Research. 74: 1736-1736. DOI: 10.1158/1538-7445.Am2014-1736 |
0.38 |
|
| 2014 |
Wu J, Huey L, Bash RE, Cohen SM, Ewend MG, Wang X, Graham DK, Frye SV, Earp HS, Miller CR. NT-38 * MerTK AS A TARGET IN GLIOBLASTOMA Neuro-Oncology. 16: v166-v167. DOI: 10.1093/Neuonc/Nou265.36 |
0.319 |
|
| 2014 |
Liu J, Yang C, Simpson C, DeRyckere D, Deusen AV, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, ... ... Frye SV, et al. Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia Acs Medicinal Chemistry Letters. 5: 1173-1173. DOI: 10.1021/Ml500328M |
0.314 |
|
| 2014 |
Earp S, Darr D, Holtzhausen A, Zimmermann A, Clark K, Hunter L, Sharpless N, Wang X, Frye S, Graham D. 503 UNC2025: A small molecule inhibitor of merTK with efficacy in mouse melanoma models European Journal of Cancer. 50: 164. DOI: 10.1016/S0959-8049(14)70629-X |
0.32 |
|
| 2014 |
Graham D, DeRyckere D, Wang X, Hill A, Zhang W, Frye S, Earp H. 352 UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemia European Journal of Cancer. 50: 114. DOI: 10.1016/S0959-8049(14)70478-2 |
0.341 |
|
| 2013 |
Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, ... ... Frye SV, et al. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry. 56: 9693-700. PMID 24219778 DOI: 10.1021/Jm501217P |
0.357 |
|
| 2013 |
Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, Allali-Hassani A, Janzen WP, Roth BL, Frye SV, Arrowsmith CH, Brown PJ, Vedadi M, Jin J. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. Journal of Medicinal Chemistry. 56: 8931-42. PMID 24102134 DOI: 10.1021/Jm401480R |
0.343 |
|
| 2013 |
James LI, Korboukh VK, Krichevsky L, Baughman BM, Herold JM, Norris JL, Jin J, Kireev DB, Janzen WP, Arrowsmith CH, Frye SV. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. Journal of Medicinal Chemistry. 56: 7358-71. PMID 24040942 DOI: 10.1021/jm400919p |
0.306 |
|
| 2013 |
Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, ... ... Frye SV, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.Mct-13-0040 |
0.372 |
|
| 2013 |
Lee-Sherick AB, Menachof K, Hill AA, Rinella S, Liu J, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. UNC1666, a Dual Mer and Flt-3 Tyrosine Kinase Small Molecule Inhibitor In Acute Myeloid Leukemia Blood. 122: 3849-3849. DOI: 10.1182/Blood.V122.21.3849.3849 |
0.354 |
|
| 2013 |
Acevedo G, Branchford BR, Law L, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Earp HS, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Mediate Synergistic Inhibition Of Platelet Aggregation In Combination With ADP/P2Y Antagonists Blood. 122: 3507-3507. DOI: 10.1182/Blood.V122.21.3507.3507 |
0.312 |
|
| 2013 |
DeRyckere D, Wang X, Hill AA, Zhang W, Stashko MA, Sather S, Cummings CE, Janzen WP, Frye SV, Earp HS, Graham DK. Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia Blood. 122: 2666-2666. DOI: 10.1182/Blood.V122.21.2666.2666 |
0.369 |
|
| 2013 |
Acevedo G, Branchford BR, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Liu J, Earp HS, Wang X, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Inhibit Platelet Aggregation In Vitro and Protect Mice From Arterial and Venous Thrombosis In Vivo Blood. 122: 2296-2296. DOI: 10.1182/Blood.V122.21.2296.2296 |
0.3 |
|
| 2013 |
Christoph S, Maag S, DeRyckere D, Graham DK, Frye SV, Earp HS, Liu J, Yang C, Zhang W, Wang X, Elmaagacli AH, Beelen D. Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma Blood. 122: 1957-1957. DOI: 10.1182/Blood.V122.21.1957.1957 |
0.343 |
|
| 2013 |
Schlegel J, Sambade M, Sather S, Moschos S, Tan A, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt G, Kuan P, Hamilton RL, Duncan LM, Miller CR, ... ... Frye SV, et al. Abstract 3037: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma. Cancer Research. 73: 3037-3037. DOI: 10.1158/1538-7445.Am2013-3037 |
0.359 |
|
| 2012 |
Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, Jin J. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. Journal of Medicinal Chemistry. 55: 7141-53. PMID 22845053 DOI: 10.1021/Jm300603Y |
0.303 |
|
| 2012 |
Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, ... ... Frye SV, et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. Acs Medicinal Chemistry Letters. 3: 129-134. PMID 22662287 DOI: 10.1021/Ml200239K |
0.362 |
|
| 2012 |
Christoph S, DeRyckere D, Schlegel J, Sather S, McGranahan A, Franzer JK, Trakhimets A, Wang X, Kireev D, Janzen W, Liu J, Yang C, Simpson C, Norris-Drouin J, Frye S, et al. Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo. Blood. 120: 2607-2607. DOI: 10.1182/Blood.V120.21.2607.2607 |
0.35 |
|
| 2012 |
Lee-Sherick AB, Menachof K, Eisenman KM, McGranahan A, McGary C, Hunsucker SA, Schlegel J, Armistead PM, Liang X, Kireev D, Janzen W, Liu J, Stashko M, Norris-Drouin J, Earp HS, ... ... Frye S, et al. Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia Blood. 120: 1317-1317. DOI: 10.1182/Blood.V120.21.1317.1317 |
0.352 |
|
| 2011 |
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, ... Frye S, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19: 17-30. PMID 21251613 DOI: 10.1016/J.Ccr.2010.12.014 |
0.346 |
|
| 2011 |
Christoph S, DeRyckere D, Sather S, Wang X, Kireev D, Janzen W, Liu J, Yang C, van Deusen A, Simpson C, Norris-Drouin J, Frye S, Earp HS, Johnson GL, Graham DK. UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL Blood. 118: 2589-2589. DOI: 10.1182/Blood.V118.21.2589.2589 |
0.354 |
|
| 2010 |
Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ, Wasney GA, Dong A, Senisterra G, Chau I, Siarheyeva A, Norris JL, Kireev DB, Jadhav A, Herold JM, Janzen WP, ... ... Frye SV, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. Journal of Medicinal Chemistry. 53: 5844-57. PMID 20614940 DOI: 10.1021/Jm100478Y |
0.315 |
|
| 2010 |
Wigle TJ, Herold JM, Senisterra GA, Vedadi M, Kireev DB, Arrowsmith CH, Frye SV, Janzen WP. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. Journal of Biomolecular Screening. 15: 62-71. PMID 20008125 DOI: 10.1177/1087057109352902 |
0.39 |
|
| 2010 |
CHEN X, HORTELANO ER, ELIEL EL, FRYE SV. ChemInform Abstract: Chelates as Intermediates in Nucleophilic Additions to Alkoxy Ketones According to Cram′s Rule (Cyclic Model). Cheminform. 23: no-no. DOI: 10.1002/chin.199226065 |
0.41 |
|
| 2003 |
Eliel EL, Lynch JE, Kume F, Frye SV. Chiral 1,3‐Oxathiane from (+)‐Pulegone: Hexahydro‐4,4,7‐trimethyl‐4H‐1,3‐benzoxathiin Organic Syntheses. 215-215. DOI: 10.1002/0471264180.Os065.26 |
0.484 |
|
| 1992 |
Chen X, Hortelano ER, Eliel EL, Frye SV. Chelates as intermediates in nucleophilic additions to alkoxy ketones according to Cram's rule (cyclic model) Journal of the American Chemical Society. 114: 1778-1784. DOI: 10.1021/Ja00031A036 |
0.415 |
|
| 1991 |
Eliel EL, Frye SV, Hortelano ER, Chen X, Bai X. Asymmetric synthesis and cram's (chelate) rule Pure and Applied Chemistry. 63: 1591-1598. DOI: 10.1351/Pac199163111591 |
0.45 |
|
| 1990 |
Chen X, Hortelano ER, Eliel EL, Frye SV. Are chelates truly intermediates in Cram's chelate rule? Journal of the American Chemical Society. 112: 6130-6131. DOI: 10.1021/Ja00172A040 |
0.396 |
|
| 1990 |
CHEN X, HORTELANO ER, ELIEL EL, FRYE SV. ChemInform Abstract: Are Chelates Truly Intermediates in Cram′s Chelate Rule? Cheminform. 21. DOI: 10.1002/chin.199047079 |
0.4 |
|
| 1988 |
Frye SV, Eliel EL. Asymmetric synthesis based on 1,3-oxathianes. 4. Mechanism of asymmetric induction in the reactions of oxathianyl ketones Journal of the American Chemical Society. 110: 484-489. DOI: 10.1021/Ja00210A028 |
0.452 |
|
| 1988 |
FRYE SV, ELIEL EL. ChemInform Abstract: Asymmetric Synthesis Based on 1,3-Oxathianes. Part 4. Mechanism of Asymmetric Induction in the Reactions of Oxathianyl Ketones. Cheminform. 19. DOI: 10.1002/chin.198818216 |
0.408 |
|
| 1987 |
Frye SV, Eliel EL, Cloux R. Rapid-injection nuclear magnetic resonance investigation of the reactivity of .alpha.- and .beta.-alkoxy ketones with dimethylmagnesium: kinetic evidence for chelation Journal of the American Chemical Society. 109: 1862-1863. DOI: 10.1021/Ja00240A047 |
0.43 |
|
| 1987 |
FRYE SV, ELIEL EL, CLOUX R. ChemInform Abstract: Rapid-Injection NMR Investigation of the Reactivity of α- and β-Alkoxy Ketones with Dimethylmagnesium: Kinetic Evidence for Chelation. Cheminform. 18. DOI: 10.1002/chin.198730135 |
0.386 |
|
| 1986 |
Frye SV, Eliel EL. Prevention of chelation by an oxygen function through protection with a triisopropyl silyl group Tetrahedron Letters. 27: 3223-3226. DOI: 10.1016/S0040-4039(00)84759-0 |
0.46 |
|
| 1986 |
FRYE SV, ELIEL EL. ChemInform Abstract: Prevention of Chelation by an Oxygen Function through Protection with a Triisopropyl Silyl Group. Chemischer Informationsdienst. 17. DOI: 10.1002/chin.198649130 |
0.382 |
|
| 1986 |
FRYE SV, ELIEL EL. ChemInform Abstract: Asymmetric Chemical Synthesis of (R)- and (S)-Citramalate in High Enantiomeric Purity. Chemischer Informationsdienst. 17. DOI: 10.1002/chin.198627078 |
0.429 |
|
| 1986 |
FRYE SV, ELIEL EL. ChemInform Abstract: Nonenzymatic Asymmetric Synthesis of (R)-(-)- and (S)-(+)-Mevalolactone in High Enantiomeric Purity. Chemischer Informationsdienst. 17. DOI: 10.1002/chin.198602195 |
0.42 |
|
| 1985 |
Frye SV, Eliel EL. Aymmetric synthesis of (R) - and (S)-citramalate in high enantiomeric purity Tetrahedron Letters. 26: 3907-3910. DOI: 10.1016/S0040-4039(00)98684-2 |
0.484 |
|
| 1985 |
Frye SV, Eliel EL. Nonenzymatic asymmetric synthesis of (R)-(-)-and (S)-(+)-mevalolactone in high enantiomeric purity Journal of Organic Chemistry. 50: 3402-3404. DOI: 10.1002/Chin.198602195 |
0.478 |
|
| 1985 |
FRYE SV, ELIEL EL. ChemInform Abstract: Asymmetric Synthesis of (R)- and (S)-Citramalate in High Enantiomeric Purity. Chemischer Informationsdienst. 16. DOI: 10.1002/chin.198550115 |
0.42 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2015 |
Wallace BD, Roberts AB, Pollet RM, Ingle JD, Biernat KA, Pellock SJ, Venkatesh MK, Guthrie L, O'Neal SK, Robinson SJ, Dollinger M, Figueroa E, McShane SR, Cohen RD, Jin J, ... Frye SV, et al. Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. Chemistry & Biology. 22: 1238-49. PMID 26364932 DOI: 10.1016/J.Chembiol.2015.08.005 |
0.299 |
|
| 2011 |
Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proceedings of the National Academy of Sciences of the United States of America. 108: 18488-93. PMID 22025698 DOI: 10.1073/Pnas.1104807108 |
0.299 |
|
| 2013 |
Jacobsen KM, Cook RS, DeRyckere D, Stanford J, Hunter DM, Wang X, Frye S, Graham DK, Earp HS. Abstract A110: Inhibition of MerTK in tumor infiltrating leukocytes decreases tumor growth in a mouse model of breast cancer Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A110 |
0.295 |
|
| 2023 |
Uguen M, Deng Y, Li F, Shell DJ, Norris-Drouin JL, Stashko MA, Ackloo S, Arrowsmith CH, James LI, Liu P, Pearce KH, Frye SV. SETDB1 Triple Tudor Domain Ligand, ( )-59, Promotes Methylation of Akt1 in Cells. Biorxiv : the Preprint Server For Biology. PMID 37214894 DOI: 10.1101/2023.05.10.539986 |
0.294 |
|
| 2012 |
Branchford BR, Law L, Sather S, Brodsky G, Earp HS, Wang X, Frye S, Graham DK, Di Paola JA. A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, iMer, the Novel MerTK Splice Variant Blood. 120: 3303-3303. DOI: 10.1182/Blood.V120.21.3303.3303 |
0.293 |
|
| 2023 |
Uguen M, Deng Y, Li F, Shell DJ, Norris-Drouin JL, Stashko MA, Ackloo S, Arrowsmith CH, James LI, Liu P, Pearce KH, Frye SV. SETDB1 Triple Tudor Domain Ligand, (,)-59, Promotes Methylation of Akt1 in Cells. Acs Chemical Biology. PMID 37556795 DOI: 10.1021/acschembio.3c00280 |
0.293 |
|
| 2017 |
Baughman BM, Wang H, An Y, Kireev D, Stashko MA, Jessen HJ, Pearce KH, Frye SV, Shears SB. Retraction: A High-Throughput Screening-Compatible Strategy for the Identification of Inositol Pyrophosphate Kinase Inhibitors. Plos One. 12: e0180272. PMID 28636659 DOI: 10.1371/Journal.Pone.0180272 |
0.292 |
|
| 2015 |
Xiao L, Kim DJ, Davis CL, McCann JV, Dunleavey JM, Vanderlinden AK, Xu N, Pattenden SG, Frye SV, Xu X, Onaitis M, Monaghan-Benson E, Burridge K, Dudley AC. Tumor Endothelial Cells with Distinct Patterns of TGFβ-Driven Endothelial-to-Mesenchymal Transition. Cancer Research. 75: 1244-54. PMID 25634211 DOI: 10.1158/0008-5472.Can-14-1616 |
0.291 |
|
| 2011 |
Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, Gao C, Ingerman LA, Kireev DB, Senisterra G, Vedadi M, Tripathy A, Brown PJ, Arrowsmith CH, Jin J, Janzen WP, ... Frye SV, et al. Small-molecule ligands of methyl-lysine binding proteins. Journal of Medicinal Chemistry. 54: 2504-11. PMID 21417280 DOI: 10.1021/jm200045v |
0.29 |
|
| 2013 |
Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, ... ... Frye SV, et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. Acs Chemical Biology. 8: 1324-34. PMID 23614352 DOI: 10.1021/Cb400133J |
0.29 |
|
| 2016 |
Stuckey JI, Dickson BM, Cheng N, Liu Y, Norris JL, Cholensky SH, Tempel W, Qin S, Huber KG, Sagum C, Black K, Li F, Huang XP, Roth BL, Baughman BM, ... ... Frye SV, et al. A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nature Chemical Biology. PMID 26807715 DOI: 10.1038/Nchembio.2007 |
0.289 |
|
| 2019 |
Frye S. Photochemical Rearrangement of a 6-Azasteroid Oxaziridine to a Novel 17β-Carbomethoxy-A-homo-B-seco-6-aza-3, 5-androstanedione Journal of the Mexican Chemical Society. 53. DOI: 10.29356/Jmcs.V53I3.994 |
0.287 |
|
| 2016 |
Pattenden SG, Simon JM, Wali A, Jayakody CN, Troutman J, McFadden AW, Wooten J, Wood CC, Frye SV, Janzen WP, Davis IJ. High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility. Proceedings of the National Academy of Sciences of the United States of America. PMID 26929321 DOI: 10.1073/pnas.1521827113 |
0.287 |
|
| 2022 |
Shell DJ, Rectenwald JM, Buttery PH, Johnson RL, Foley CA, Guduru SKR, Uguen M, Rubiano JS, Zhang X, Li F, Norris-Drouin JL, Axtman M, Brian Hardy P, Vedadi M, Frye SV, et al. Discovery of Hit Compounds for Methyl-lysine Reader Proteins from a Target Class DNA-Encoded Library. Slas Discovery : Advancing Life Sciences R & D. PMID 36272689 DOI: 10.1016/j.slasd.2022.10.003 |
0.287 |
|
| 2014 |
Wong K, Tan A, Pitts T, Klauck P, Earp S, Frye S, Wang X, Graham D, Eckhardt S. 375 MER as a novel therapeutic target in colorectal cancer European Journal of Cancer. 50: 120-121. DOI: 10.1016/S0959-8049(14)70501-5 |
0.286 |
|
| 2013 |
Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, ... ... Frye SV, et al. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry. 56: 9683-92. PMID 24195762 DOI: 10.1021/Jm401387J |
0.282 |
|
| 2011 |
Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, DiMaggio PA, Wasney GA, Siarheyeva A, Dong A, Tempel W, Wang S, Chen X, Chau I, ... ... Frye SV, et al. Erratum: A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells Nature Chemical Biology. 7: 648-648. DOI: 10.1038/Nchembio0911-648C |
0.281 |
|
| 2017 |
Barnash KD, The J, Norris-Drouin JL, Cholensky SH, Worley BM, Li F, Stuckey JI, Brown PJ, Vedadi M, Arrowsmith CH, Frye SV, James LI. Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2. Acs Combinatorial Science. PMID 28165227 DOI: 10.1021/acscombsci.6b00174 |
0.278 |
|
| 2017 |
Baughman BM, Pattenden SG, Norris JL, James LI, Frye SV. Retraction of "The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer". Acs Chemical Biology. PMID 29256585 DOI: 10.1021/Acschembio.7B01061 |
0.277 |
|
| 2019 |
Rectenwald JM, Hardy PB, Norris-Drouin JL, Cholensky SH, James LI, Frye SV, Pearce KH. A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins. Slas Discovery : Advancing Life Sciences R & D. 2472555219844569. PMID 31017815 DOI: 10.1177/2472555219844569 |
0.275 |
|
| 2023 |
Shell DJ, Foley CA, Wang Q, Smith CM, Guduru SKR, Zeng H, Dong A, Norris-Drouin JL, Axtman M, Hardy PB, Gupta G, Halabelian L, Frye SV, James LI, Pearce KH. Discovery of a 53BP1 Small Molecule Antagonist Using a Focused DNA-Encoded Library Screen. Journal of Medicinal Chemistry. 66: 14133-14149. PMID 37782247 DOI: 10.1021/acs.jmedchem.3c01192 |
0.274 |
|
| 2014 |
Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, ... ... Frye SV, et al. Correction to Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors Journal of Medicinal Chemistry. 57: 7141-7141. DOI: 10.1021/Jm501216S |
0.272 |
|
| 2021 |
Engelberg IA, Liu J, Norris-Drouin JL, Cholensky SH, Ottavi SA, Frye SV, Kutateladze TG, James LI. Discovery of an H3K36me3-Derived Peptidomimetic Ligand with Enhanced Affinity for Plant Homeodomain Finger Protein 1 (PHF1). Journal of Medicinal Chemistry. PMID 33999620 DOI: 10.1021/acs.jmedchem.1c00430 |
0.271 |
|
| 2013 |
Liu J, Zhang W, Stashko MA, Deryckere D, Cummings CT, Hunter D, Yang C, Jayakody CN, Cheng N, Simpson C, Norris-Drouin J, Sather S, Kireev D, Janzen WP, Earp HS, ... ... Frye SV, et al. UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry. 65: 83-93. PMID 23693152 DOI: 10.1016/J.Ejmech.2013.03.035 |
0.271 |
|
| 2016 |
Wang X, Liu J, Zhang W, Stashko MA, Nichols J, Miley MJ, Norris-Drouin J, Chen Z, Machius M, DeRyckere D, Wood E, Graham DK, Earp HS, Kireev D, Frye SV. Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. Acs Medicinal Chemistry Letters. 7: 1044-1049. PMID 27994735 DOI: 10.1021/Acsmedchemlett.6B00221 |
0.267 |
|
| 2024 |
Kong D, Tian Q, Chen Z, Zheng H, Stashko MA, Yan D, Earp HS, Frye SV, DeRyckere D, Kireev D, Graham DK, Wang X. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors. Journal of Medicinal Chemistry. PMID 38556760 DOI: 10.1021/acs.jmedchem.4c00148 |
0.266 |
|
| 2016 |
Barnash KD, Lamb KN, Stuckey JI, Norris-Drouin JL, Cholensky SH, Kireev DB, Frye SV, James LI. Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing. Acs Chemical Biology. PMID 27356154 DOI: 10.1021/acschembio.6b00415 |
0.265 |
|
| 2018 |
Puhl-Rubio AC, Stashko MA, Wang H, Hardy PB, Tyagi V, Li B, Wang X, Kireev D, Jessen HJ, Frye SV, Shears SB, Pearce KH. Use of Protein Kinase-Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors. Slas Discovery : Advancing Life Sciences R & D. 2472555218775323. PMID 29842835 DOI: 10.1177/2472555218775323 |
0.264 |
|
| 2020 |
Vaughan RM, Kupai A, Foley CA, Sagum CA, Tibben BM, Eden HE, Tiedemann RL, Berryhill CA, Patel V, Shaw KM, Krajewski K, Strahl BD, Bedford MT, Frye SV, Dickson BM, et al. The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells. Epigenetics & Chromatin. 13: 44. PMID 33097091 DOI: 10.1186/s13072-020-00366-4 |
0.264 |
|
| 2013 |
Liu F, Li F, Ma A, Dobrovetsky E, Dong A, Gao C, Korboukh I, Liu J, Smil D, Brown PJ, Frye SV, Arrowsmith CH, Schapira M, Vedadi M, Jin J. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. Journal of Medicinal Chemistry. 56: 2110-24. PMID 23445220 DOI: 10.1021/Jm3018332 |
0.263 |
|
| 2016 |
Zhou H, Che X, Bao G, Wang N, Peng L, Barnash KD, Frye SV, James LI, Bai X. Design, synthesis, and protein methyltransferase activity of a unique set of constrained amine containing compounds. Bioorganic & Medicinal Chemistry Letters. PMID 27528434 DOI: 10.1016/j.bmcl.2016.08.004 |
0.262 |
|
| 2011 |
Herold JM, Ingerman LA, Gao C, Frye SV. Drug discovery toward antagonists of methyl-lysine binding proteins. Current Chemical Genomics. 5: 51-61. PMID 22145013 DOI: 10.2174/1875397301005010051 |
0.261 |
|
| 2021 |
Lamb KN, Dishman SN, Waybright JM, Engelberg IA, Rectenwald JM, Norris-Drouin JL, Cholensky SH, Pearce KH, James LI, Frye SV. Discovery of Potent Peptidomimetic Antagonists for Heterochromatin Protein 1 Family Proteins. Acs Omega. 7: 716-732. PMID 35036738 DOI: 10.1021/acsomega.1c05381 |
0.261 |
|
| 2019 |
Yan D, Huelse J, Parker R, Wang X, Frye S, Earp H, Deryckere D, Graham D. P1.18 MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S1147. DOI: 10.1016/J.Jtho.2019.09.075 |
0.261 |
|
| 2015 |
Cummings CT, Zhang W, Davies KD, Kirkpatrick GD, Zhang D, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. Small molecule inhibition of MERTK is efficacious in non-small cell lung cancer models independent of driver oncogene status. Molecular Cancer Therapeutics. PMID 26162689 DOI: 10.1158/1535-7163.Mct-15-0116 |
0.259 |
|
| 2018 |
Suh JL, Watts B, Stuckey JI, Norris-Drouin JL, Cholensky SH, Dickson BM, An Y, Mathea S, Salah E, Knapp S, Khan A, Adams AT, Strahl BD, Sagum CA, Bedford MT, ... ... Frye SV, et al. Correction to "Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID subunit 1". Biochemistry. PMID 30485080 DOI: 10.1021/Acs.Biochem.8B01187 |
0.259 |
|
| 2019 |
Barnes DE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 2192A: Combined MERTK and ROCK1/2 inhibition as a potential therapeutic strategy for AML Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2192A |
0.258 |
|
| 2016 |
Stuckey JI, Simpson C, Norris-Drouin JL, Cholensky SH, Lee J, Pasca R, Cheng N, Dickson BM, Pearce KH, Frye SV, James LI. Structure-activity relationships and kinetic studies of peptidic antagonists of CBX chromodomains. Journal of Medicinal Chemistry. PMID 27571219 DOI: 10.1021/Acs.Jmedchem.6B00801 |
0.256 |
|
| 2013 |
James LI, Frye SV. Targeting chromatin readers. Clinical Pharmacology and Therapeutics. 93: 312-4. PMID 23403847 DOI: 10.1038/clpt.2013.6 |
0.254 |
|
| 2018 |
McDaniel NK, Cummings CT, Iida M, Hulse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, et al. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics. PMID 30093568 DOI: 10.1158/1535-7163.Mct-17-1239 |
0.254 |
|
| 2021 |
Engelberg IA, Foley CA, James LI, Frye SV. Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine. Current Opinion in Chemical Biology. 63: 132-144. PMID 33852996 DOI: 10.1016/j.cbpa.2021.03.002 |
0.252 |
|
| 2015 |
Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, ... ... Frye SV, et al. Corrigendum: The promise and peril of chemical probes. Nature Chemical Biology. 11: 887. PMID 26485080 DOI: 10.1038/Nchembio1115-887C |
0.25 |
|
| 2018 |
Zhao J, Zhang D, Zhang W, Stashko MA, DeRyckere D, Vasileiadi E, Parker RE, Hunter D, Liu Q, Zhang Y, Norris-Drouin JL, Li B, Drewry D, Kireev DB, Graham DK, ... ... Frye SV, et al. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry. PMID 30347155 DOI: 10.1021/Acs.Jmedchem.8B01229 |
0.249 |
|
| 2023 |
Bashore FM, Foley CA, Ong HW, Rectenwald JM, Hanley RP, Norris-Drouin JL, Cholensky SH, Mills CA, Pearce KH, Herring LE, Kireev D, Frye SV, James LI. PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components. Acs Chemical Biology. PMID 36877831 DOI: 10.1021/acschembio.2c00804 |
0.247 |
|
| 2013 |
James LI, Barsyte-Lovejoy D, Zhong N, Krichevsky L, Korboukh VK, Herold JM, MacNevin CJ, Norris JL, Sagum CA, Tempel W, Marcon E, Guo H, Gao C, Huang XP, Duan S, ... ... Frye SV, et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nature Chemical Biology. 9: 184-91. PMID 23292653 DOI: 10.1038/Nchembio.1157 |
0.247 |
|
| 2021 |
Zheng H, Zhao J, Li B, Zhang W, Stashko MA, Minson KA, Huey MG, Zhou Y, Earp HS, Kireev D, Graham DK, DeRyckere D, Frye SV, Wang X. UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry. 220: 113534. PMID 34038857 DOI: 10.1016/j.ejmech.2021.113534 |
0.246 |
|
| 2021 |
Hoque M, Wai Wong S, Recasens A, Abbassi R, Nguyen N, Zhang D, Stashko MA, Wang X, Frye S, Day BW, Baell J, Munoz L. MerTK activity is not necessary for the proliferation of glioblastoma stem cells. Biochemical Pharmacology. 114437. PMID 33571503 DOI: 10.1016/j.bcp.2021.114437 |
0.246 |
|
| 2016 |
McIver A, Zhang W, Liu Q, Jiang X, Stashko M, Nichols J, Miley M, Norris-Drouin J, Machius M, DeRyckere D, Wood E, Graham D, Earp HS, Kireev D, Frye S, et al. Discovery of Macrocyclic Pyrimidines as MerTK-specific Inhibitors. Chemmedchem. PMID 28032464 DOI: 10.1002/Cmdc.201600589 |
0.244 |
|
| 2018 |
Lee-Sherick A, Jacobsen K, Henry CJ, Parker R, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis Blood. 132: 4019-4019. DOI: 10.1182/Blood-2018-99-119818 |
0.243 |
|
| 2016 |
Sufit A, Lee-Sherick AB, DeRyckere D, Rupji M, Dwivedi B, Varella-Garcia M, Pierce AM, Kowalski J, Wang X, Frye SV, Earp HS, Keating AK, Graham DK. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. Plos One. 11: e0165107. PMID 27783662 DOI: 10.1371/Journal.Pone.0165107 |
0.239 |
|
| 2013 |
Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, ... ... Frye SV, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation. 123: 2257-67. PMID 23585477 DOI: 10.1172/Jci67816 |
0.239 |
|
| 2013 |
Blancafort P, Jin J, Frye S. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Molecular Pharmacology. 83: 563-76. PMID 23150486 DOI: 10.1124/Mol.112.080697 |
0.235 |
|
| 2011 |
Liu F, Barsyte-Lovejoy D, Allali-Hassani A, He Y, Herold JM, Chen X, Yates CM, Frye SV, Brown PJ, Huang J, Vedadi M, Arrowsmith CH, Jin J. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. Journal of Medicinal Chemistry. 54: 6139-50. PMID 21780790 DOI: 10.1021/jm200903z |
0.232 |
|
| 2023 |
Vital T, Wali A, Butler KV, Xiong Y, Foster JP, Marcel SS, McFadden AW, Nguyen VU, Bailey BM, Lamb KN, James LI, Frye SV, Mosely AL, Jin J, Pattenden SG, et al. MS0621, a novel small-molecule modulator of Ewing sarcoma chromatin accessibility, interacts with an RNA-associated macromolecular complex and influences RNA splicing. Frontiers in Oncology. 13: 1099550. PMID 36793594 DOI: 10.3389/fonc.2023.1099550 |
0.229 |
|
| 2012 |
Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, ... ... Frye SV, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/J.Cell.2012.02.053 |
0.229 |
|
| 2015 |
Baughman BM, Pattenden SG, Norris JL, James LI, Frye SV. The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer. Acs Chemical Biology. PMID 26317848 DOI: 10.1021/acschembio.5b00632 |
0.228 |
|
| 2013 |
Frye SV. Drug discovery in academic institutions. Hematology. American Society of Hematology. Education Program. 2013: 300-5. PMID 24319195 DOI: 10.1182/asheducation-2013.1.300 |
0.225 |
|
| 2023 |
Spangler CJ, Skrajna A, Foley CA, Nguyen A, Budziszewski GR, Azzam DN, Arteaga EC, Simmons HC, Smith CB, Wesley NA, Wilkerson EM, McPherson JE, Kireev D, James LI, Frye SV, et al. Structural basis of paralog-specific KDM2A/B nucleosome recognition. Nature Chemical Biology. PMID 36797403 DOI: 10.1038/s41589-023-01256-y |
0.225 |
|
| 2016 |
James LI, Frye SV. Chemical probes for methyl lysine reader domains. Current Opinion in Chemical Biology. 33: 135-141. PMID 27348158 DOI: 10.1016/j.cbpa.2016.06.004 |
0.223 |
|
| 2011 |
Gao C, Herold JM, Kireev D, Wigle T, Norris JL, Frye S. Biophysical probes reveal a "compromise" nature of the methyl-lysine binding pocket in L3MBTL1. Journal of the American Chemical Society. 133: 5357-62. PMID 21428286 DOI: 10.1021/ja110432e |
0.223 |
|
| 2001 |
Bramson HN, Corona J, Davis ST, Dickerson SH, Edelstein M, Frye SV, Gampe RT, Harris PA, Hassell A, Holmes WD, Hunter RN, Lackey KE, Lovejoy B, Luzzio MJ, Montana V, et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. Journal of Medicinal Chemistry. 44: 4339-58. PMID 11728181 DOI: 10.1021/jm010117d |
0.221 |
|
| 2016 |
Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. Jci Insight. 1: e85630. PMID 27158668 DOI: 10.1172/Jci.Insight.85630 |
0.22 |
|
| 2010 |
Kireev D, Wigle TJ, Norris-Drouin J, Herold JM, Janzen WP, Frye SV. Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds. Journal of Medicinal Chemistry. 53: 7625-31. PMID 20931980 DOI: 10.1021/jm1007374 |
0.22 |
|
| 2018 |
Müller S, Ackloo S, Arrowsmith CH, Bauser M, Baryza JL, Blagg J, Böttcher J, Bountra C, Brown PJ, Bunnage ME, Carter AJ, Damerell D, Dötsch V, Drewry DH, Edwards AM, ... ... Frye SV, et al. Author response: Donated chemical probes for open science Elife. DOI: 10.7554/Elife.34311.009 |
0.22 |
|
| 2013 |
Camerino MA, Zhong N, Dong A, Dickson BM, James LI, Baughman BM, Norris JL, Kireev DB, Janzen WP, Arrowsmith CH, Frye SV. The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface. Medchemcomm. 4: 1501-1507. PMID 24466405 DOI: 10.1039/C3Md00197K |
0.218 |
|
| 2010 |
Janzen WP, Wigle TJ, Jin J, Frye SV. Epigenetics: Tools and Technologies. Drug Discovery Today. Technologies. 7: e59-e65. PMID 21243036 DOI: 10.1016/j.ddtec.2010.07.004 |
0.217 |
|
| 2014 |
Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, ... ... Frye SV, et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. Journal of Medicinal Chemistry. 57: 7031-41. PMID 25068800 DOI: 10.1021/Jm500749D |
0.215 |
|
| 2001 |
Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe Jr RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science (New York, N.Y.). 291: 134-7. PMID 11141566 DOI: 10.1126/science.291.5501.134 |
0.214 |
|
| 2009 |
Frye SV, Johnson GL. Inhibitors paradoxically prime kinases. Nature Chemical Biology. 5: 448-9. PMID 19465930 DOI: 10.1038/Nchembio.F.11 |
0.21 |
|
| 2010 |
Wigle TJ, Provencher LM, Norris JL, Jin J, Brown PJ, Frye SV, Janzen WP. Accessing protein methyltransferase and demethylase enzymology using microfluidic capillary electrophoresis. Chemistry & Biology. 17: 695-704. PMID 20659682 DOI: 10.1016/j.chembiol.2010.04.014 |
0.21 |
|
| 2000 |
Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, Veal JM, Wood ER. The discovery of potent cRaf1 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 10: 223-6. PMID 10698440 DOI: 10.1016/S0960-894X(99)00668-X |
0.203 |
|
| 2011 |
Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, Dong A, Tempel W, Wang SC, Chen X, Chau I, ... ... Frye SV, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature Chemical Biology. 7: 566-74. PMID 21743462 DOI: 10.1038/Nchembio.599 |
0.199 |
|
| 2013 |
Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, et al. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. Plos One. 8: e66755. PMID 23826126 DOI: 10.1371/Journal.Pone.0066755 |
0.197 |
|
| 2023 |
Du Y, Bradshaw WJ, Leisner TM, Annor-Gyamfi JK, Qian K, Bashore FM, Sikdar A, Nwogbo FO, Ivanov AA, Frye SV, Gileadi O, Brennan PE, Levey AI, Axtman AD, Pearce KH, et al. Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. Biorxiv : the Preprint Server For Biology. PMID 37292860 DOI: 10.1101/2023.05.22.541727 |
0.196 |
|
| 2018 |
Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Karni R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. Molecular Cancer Therapeutics. PMID 30482852 DOI: 10.1158/1535-7163.Mct-18-0456 |
0.196 |
|
| 2022 |
Yan D, Huelse JM, Kireev D, Tan Z, Chen L, Goyal S, Wang X, Frye SV, Behera M, Schneider F, Ramalingam SS, Owonikoko TK, Earp HS, DeRyckere D, Graham DK. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. The Journal of Clinical Investigation. PMID 35708914 DOI: 10.1172/JCI150517 |
0.195 |
|
| 2016 |
Frye SV, Jin J. Novel Therapeutics Targeting Epigenetics: New Molecules, New Methods. Acs Medicinal Chemistry Letters. 7: 123. PMID 26985299 DOI: 10.1021/acsmedchemlett.6b00037 |
0.187 |
|
| 2016 |
Frye SV, Jin J. Novel Therapeutics Targeting Epigenetics: New Molecules, New Methods Acs Medicinal Chemistry Letters. 7: 123. DOI: 10.1021/acsmedchemlett.6b00037 |
0.187 |
|
| 2015 |
Frye SV, James LI. Small-molecule modulation of methyl-lysine-mediated interactions Histone Recognition. 243-272. DOI: 10.1007/978-3-319-18102-8_12 |
0.186 |
|
| 2021 |
Rohde JM, Karavadhi S, Pragani R, Liu L, Fang Y, Zhang W, McIver A, Zheng H, Liu Q, Davis MI, Urban DJ, Lee TD, Cheff DM, Hollingshead M, Henderson MJ, ... ... Frye S, et al. Discovery and Optimization of 2-1λ-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer. Journal of Medicinal Chemistry. PMID 33822623 DOI: 10.1021/acs.jmedchem.1c00019 |
0.186 |
|
| 2023 |
Du Y, Bradshaw WJ, Leisner TM, Annor-Gyamfi JK, Qian K, Bashore FM, Sikdar A, Nwogbo FO, Ivanov AA, Frye SV, Gileadi O, Brennan PE, Levey AI, Axtman AD, Pearce KH, et al. Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's disease. The Journal of Biological Chemistry. 105382. PMID 37866628 DOI: 10.1016/j.jbc.2023.105382 |
0.183 |
|
| 2012 |
Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, MacHius M, Johnson GL, ... ... Frye SV, et al. Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia Acs Medicinal Chemistry Letters. 3: 129-134. DOI: 10.1021/ml200239k |
0.183 |
|
| 2009 |
Liu F, Chen X, Allali-Hassani A, Quinn AM, Wasney GA, Dong A, Barsyte D, Kozieradzki I, Senisterra G, Chau I, Siarheyeva A, Kireev DB, Jadhav A, Herold JM, Frye SV, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. Journal of Medicinal Chemistry. 52: 7950-3. PMID 19891491 DOI: 10.1021/Jm901543M |
0.181 |
|
| 2016 |
DeRyckere D, Lee Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GD, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a MerTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27649555 DOI: 10.1158/1078-0432.Ccr-16-1330 |
0.177 |
|
| 2017 |
Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR. MerTK as a therapeutic target in glioblastoma. Neuro-Oncology. PMID 28605477 DOI: 10.1093/Neuonc/Nox111 |
0.172 |
|
| 1999 |
Frye SV. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chemistry & Biology. 6: R3-7. PMID 9889153 DOI: 10.1016/S1074-5521(99)80013-1 |
0.172 |
|
| 2018 |
Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 3. PMID 30385715 DOI: 10.1172/Jci.Insight.97941 |
0.166 |
|
| 2018 |
Müller S, Ackloo S, Arrowsmith CH, Bauser M, Baryza JL, Blagg J, Böttcher J, Bountra C, Brown PJ, Bunnage ME, Carter AJ, Damerell D, Dötsch V, Drewry DH, Edwards AM, ... ... Frye SV, et al. Donated chemical probes for open science. Elife. 7. PMID 29676732 DOI: 10.7554/Elife.34311 |
0.166 |
|
| 1995 |
Frye SV, Haffner CD, Maloney PR, Hiner RN, Dorsey GF, Noe RA, Unwalla RJ, Batchelor KW, Bramson HN, Stuart JD, Schweiker SL, Van Arnold J, Bickett DM, Moss ML, Tian G, et al. Structure-activity relationships for inhibition of type 1 and 2 human 5α-reductase and human adrenal 3β-hydroxy-Δ5-steroid dehydrogenase/ 3-keto-Δ5-steroid isomerase by 6-azaandrost-4-en-3-ones: Optimization of the C17 substituent Journal of Medicinal Chemistry. 38: 2621-2627. PMID 7629802 DOI: 10.1021/jm00014a015 |
0.165 |
|
| 2011 |
Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery Nature Reviews Drug Discovery. 10: 409-410. PMID 21629285 DOI: 10.1038/Nrd3462 |
0.164 |
|
| 2015 |
Frye SV. Unlocking the potential of chemical probes for methyl-lysine reader proteins. Future Medicinal Chemistry. 7: 1831-3. PMID 26393394 DOI: 10.4155/fmc.15.119 |
0.16 |
|
| 2022 |
Summers RJ, Jain J, Vasileiadi E, Smith B, Chimenti ML, Yeung TY, Kelvin J, Wang X, Frye SV, Earp HS, Tyner JW, Dreaden EC, DeRyckere D, Graham DK. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Cancers. 14. PMID 36551626 DOI: 10.3390/cancers14246142 |
0.157 |
|
| 1995 |
Tian G, Mook RA, Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry. 34: 13453-9. PMID 7577933 DOI: 10.1021/BI00041A024 |
0.153 |
|
| 2019 |
Stuckey JI, Dickson BM, Cheng N, Liu Y, Norris JL, Cholensky SH, Tempel W, Qin S, Huber KG, Sagum C, Black K, Li F, Huang XP, Roth BL, Baughman BM, ... ... Frye SV, et al. Addendum: A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nature Chemical Biology. PMID 30842648 DOI: 10.1038/s41589-019-0242-5 |
0.151 |
|
| 2020 |
Su YT, Butler M, Zhang M, Zhang W, Song H, Hwang L, Tran AD, Bash RE, Schorzman AN, Pang Y, Yu G, Zamboni WC, Wang X, Frye SV, Miller CR, et al. MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. Neuro-Oncology Advances. 2: vdaa065. PMID 32642716 DOI: 10.1093/noajnl/vdaa065 |
0.147 |
|
| 2012 |
Rittiner JE, Korboukh I, Hull-Ryde EA, Jin J, Janzen WP, Frye SV, Zylka MJ. AMP is an adenosine A1 receptor agonist. The Journal of Biological Chemistry. 287: 5301-9. PMID 22215671 DOI: 10.1074/jbc.M111.291666 |
0.147 |
|
| 2023 |
Bashore FM, Annor-Gyamfi J, Du Y, Katis V, Nwogbo F, Flax RG, Frye SV, Pearce KH, Fu H, Willson TM, Drewry DH, Axtman AD. Fused Tetrahydroquinolines Are Interfering with Your Assay. Journal of Medicinal Chemistry. 66: 14434-14446. PMID 37874947 DOI: 10.1021/acs.jmedchem.3c01277 |
0.145 |
|
| 1994 |
Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Cribbs CM, Wheeler TN, Ray JA, Andrews RC. 6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase. Journal of Medicinal Chemistry. 37: 2352-60. PMID 8057283 DOI: 10.1021/jm00041a014 |
0.139 |
|
| 2017 |
Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, ... Frye SV, et al. The small molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis : Jth. PMID 29045015 DOI: 10.1111/Jth.13875 |
0.137 |
|
| 2021 |
Wong SW, Vivash L, Mudududdla R, Nguyen N, Hermans SJ, Shackleford DM, Field J, Xue L, Aprico A, Hancock NC, Haskali M, Stashko MA, Frye SV, Wang X, Binder MD, et al. Development of [F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. European Journal of Medicinal Chemistry. 226: 113822. PMID 34563964 DOI: 10.1016/j.ejmech.2021.113822 |
0.136 |
|
| 2021 |
Müller S, Ackloo S, Al Chawaf A, Al-Lazikani B, Antolin A, Baell JB, Beck H, Beedie S, Betz UAK, Bezerra GA, Brennan PE, Brown D, Brown PJ, Bullock AN, Carter AJ, ... ... Frye SV, et al. Target 2035 - update on the quest for a probe for every protein. Rsc Medicinal Chemistry. 13: 13-21. PMID 35211674 DOI: 10.1039/d1md00228g |
0.136 |
|
| 2006 |
Frye SV. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Current Topics in Medicinal Chemistry. 6: 405-21. PMID 16719800 |
0.13 |
|
| 1996 |
Moss ML, Kuzmič P, Stuart JD, Tian G, Peranteau AG, Frye SV, Kadwell SH, Kost TA, Overton LK, Patel IR. Inhibition of human steroid 5α reductases type I and II by 6-aza-steroids: Structural determinants of one-step vs two-step mechanism Biochemistry. 35: 3457-3464. PMID 8639496 DOI: 10.1021/BI952472+ |
0.128 |
|
| 2012 |
Herold JM, James LI, Korboukh VK, Gao C, Coil KE, Bua DJ, Norris JL, Kireev DB, Brown PJ, Jin J, Janzen WP, Gozani O, Frye SV. Structure-activity relationships of methyl-lysine reader antagonists Medchemcomm. 3: 45-51. DOI: 10.1039/c1md00195g |
0.127 |
|
| 2014 |
Wright BD, Loo L, Street SE, Ma A, Taylor-Blake B, Stashko MA, Jin J, Janzen WP, Frye SV, Zylka MJ. The lipid kinase PIP5K1C regulates pain signaling and sensitization. Neuron. 82: 836-47. PMID 24853942 DOI: 10.1016/J.Neuron.2014.04.006 |
0.125 |
|
| 2017 |
Barnash KD, James LI, Frye SV. Target class drug discovery. Nature Chemical Biology. 13: 1053-1056. PMID 28926557 DOI: 10.1038/nchembio.2473 |
0.123 |
|
| 1993 |
Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Batchelor KW, Neal Bramson H, Darren Stuart J, Schweiker SL, Van Arnold J, Mark Bickett D, Moss ML, Tian G, Unwalla RJ, et al. 6-azasteroids: Potent dual inhibitors of human type 1 and 2 steroid 5α-reductase Journal of Medicinal Chemistry®. 36: 4313-4315. PMID 8277514 DOI: 10.1021/JM00078A022 |
0.119 |
|
| 2012 |
Korboukh I, Hull-Ryde EA, Rittiner JE, Randhawa AS, Coleman J, Fitzpatrick BJ, Setola V, Janzen WP, Frye SV, Zylka MJ, Jin J. Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice. Journal of Medicinal Chemistry. 55: 6467-77. PMID 22738238 DOI: 10.1021/Jm3004834 |
0.115 |
|
| 1998 |
Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharmaceutical Biotechnology. 11: 393-422. PMID 9760689 DOI: 10.1007/0-306-47384-4_17 |
0.11 |
|
| 2010 |
FRYE SV, HAFFNER CD, MALONEY PR, MOOK RAJ, DORSEY GFJ, HINER RN, BATCHELOR KW, BRAMSON HN, STUART JD, SCHWEIKER SL, VAN ARNOLD J, BICKETT DM, MOSS ML, TIAN G, UNWALLA RJ, et al. ChemInform Abstract: 6-Azasteroids: Potent Dual Inhibitors of Human Type 1 and 2 Steroid 5. alpha.-Reductase. Cheminform. 25: no-no. DOI: 10.1002/chin.199426234 |
0.106 |
|
| 2022 |
Laufer S, Bajorath J, Gehringer M, Gray N, Frye S, Lindsley CW. Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected? Journal of Medicinal Chemistry. PMID 35512193 DOI: 10.1021/acs.jmedchem.2c00623 |
0.105 |
|
| 2015 |
Frye SV, Arkin MR, Arrowsmith CH, Conn PJ, Glicksman MA, Hull-Ryde EA, Slusher BS. Tackling reproducibility in academic preclinical drug discovery. Nature Reviews. Drug Discovery. 14: 733-4. PMID 26388229 DOI: 10.1038/Nrd4737 |
0.1 |
|
| 2022 |
Müller S, Frye S, Baell J. The future of chemical probes is diversity. Rsc Medicinal Chemistry. 13: 1438. PMID 36561071 DOI: 10.1039/d2md90036j |
0.1 |
|
| 2023 |
Cruz Cruz J, Allison KC, Page LS, Jenkins AJ, Wang X, Earp HS, Frye SV, Graham DK, Verneris MR, Lee-Sherick AB. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. Frontiers in Immunology. 14: 1146721. PMID 36960055 DOI: 10.3389/fimmu.2023.1146721 |
0.098 |
|
| 2010 |
FRYE SV, HAFFNER CD, MALONEY PR, MOOK RAJ, DORSEY GFJ, HINER RN, CRIBBS CM, WHEELER TN, RAY JA, ANDREWS RC, BATCHELOR KW, BRAMSON HN, STUART JD, SCHWEIKER SL, VAN ARNOLD J, et al. ChemInform Abstract: 6-Azasteroids: Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5α-Reductase and Human Adrenal 3β-Hydroxy-. delta.5-steroid Dehydrogenase/3-Keto-δ5-steroid Isomerase. Cheminform. 25: no-no. DOI: 10.1002/CHIN.199451227 |
0.094 |
|
| 2010 |
Frye SV. The art of the chemical probe. Nature Chemical Biology. 6: 159-161. PMID 20154659 DOI: 10.1038/nchembio.296 |
0.087 |
|
| 2015 |
Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, ... ... Frye SV, et al. The promise and peril of chemical probes. Nature Chemical Biology. 11: 536-41. PMID 26196764 DOI: 10.1038/Nchembio.1867 |
0.077 |
|
| 2011 |
Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. Too many roads not taken. Nature. 470: 163-5. PMID 21307913 DOI: 10.1038/470163A |
0.075 |
|
| 2022 |
Potjewyd FM, Annor-Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, ... ... Frye SV, et al. Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology. Alzheimer's & Dementia (New York, N. Y.). 8: e12253. PMID 35434254 DOI: 10.1002/trc2.12253 |
0.074 |
|
| 2014 |
Slusher BS, Conn PJ, Frye S, Glicksman M, Arkin M. Bringing together the academic drug discovery community. Nature Reviews. Drug Discovery. 12: 811-2. PMID 24172316 DOI: 10.1038/Nrd4155 |
0.073 |
|
| 2022 |
Potjewyd FM, Annor-Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, ... ... Frye SV, et al. AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery. Alzheimer's & Dementia (New York, N. Y.). 8: e12246. PMID 35475262 DOI: 10.1002/trc2.12246 |
0.064 |
|
| 2020 |
Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 5. PMID 33268596 DOI: 10.1172/jci.insight.145847 |
0.063 |
|
| 2010 |
FRYE SV, JOHNSON MC, VALVANO NL. ChemInform Abstract: Synthesis of 2-Aminobenzophenones via Rapid Halogen-Lithium Exchange in the Presence of a 2-Amino-N-methoxy-N-methylbenzamide. Cheminform. 22: no-no. DOI: 10.1002/CHIN.199142143 |
0.058 |
|
| 1991 |
Frye SV, Johnson MC, Valvano NL. Synthesis of 2-aminobenzophenones via rapid halogen-lithium exchange in the presence of a 2-amino-N-methoxy-N-methylbenzamide The Journal of Organic Chemistry. 56: 3750-3752. DOI: 10.1021/JO00011A066 |
0.051 |
|
| 2002 |
Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT, Grifffen RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, et al. Retraction. Science (New York, N.Y.). 298: 2327. PMID 12526115 DOI: 10.1126/science.298.5602.2327b |
0.024 |
|
| 2012 |
Frye S. Stephen Frye. Interview by Asher Mullard. Nature Reviews. Drug Discovery. 11: 346. PMID 22495334 DOI: 10.1038/nrd3726 |
0.01 |
|
| 1976 |
Frye S. Scripts People Live(?): A Critical Book Review Transactional Analysis Bulletin. 6: 329-332. DOI: 10.1177/036215377600600330 |
0.01 |
|
| Hide low-probability matches. |
